Pulmonary alveolar proteinosis: A new autoimmune disease

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 22, Issue SUPPL. 1, 2005, Pages

  Costabel, Ulrich ^a,c   Guzman, Josune ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c RUHRLANDKLINIK   (Germany)

Author keywords

Pathogenesis; Pulmonary alveolar proteinosis; Therapy

Indexed keywords

AUTOANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLINOSITOL; PHOSPHOLIPID; SPHINGOMYELIN; SURFACTANT; SURFACTANT PROTEIN B;

ADULT; AGED; AUTOIMMUNE DISEASE; CHEMICAL ANALYSIS; CONFERENCE PAPER; DRUG ACCUMULATION; FEMALE; HISTOPATHOLOGY; HUMAN; INFLAMMATORY INFILTRATE; LUNG ALVEOLUS MACROPHAGE; LUNG ALVEOLUS PROTEINOSIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN INTOLERANCE; RARE DISEASE;

AUTOIMMUNE DISEASES; BIOPSY, NEEDLE; CLINICAL TRIALS, PHASE II; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PULMONARY ALVEOLAR PROTEINOSIS; REMISSION, SPONTANEOUS; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 31544444192     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (58)

1. Rosen SH, Castleman B, Liebow AA: Pulmonary alveolar proteinosis. N Engl J Med 1958; 258: 1123-42.
2. Shah PL, Hansell D, Lawson PR, Reid KB, Morgan C: Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis. Thorax 2000; 55: 67-77.
3. Seymour JF, Presneill JJ: Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med 2002; 166: 215-35.
4. Trapnell BC, Whitsett JA, Nakata K: Pulmonary alveolar proteinosis. N Engl J Med 2003; 349: 2527-39.
5. Costabel U, Corrin B: Alveolar proteinosis. In: Gibson GJ, Geddes DM, Costabel U, Sterk PJ, Corrin B, (eds). Respiratory Medicine. Third Ed. London: Saunders 2003, pp. 1676-82.
6. Teja K, Cooper PH, Squires JE, Schnatterly PT: Pulmonary alveolar proteinosis in four siblings. N Engl J Med 1981; 305: 1390-2.
7. Lin Z, deMello DE, Wallot M, Floros J: An SP-B gene mutation responsible for SP-B deficiency in fatal congenital alveolar proteinosis: evidence for a mutation hotspot in exon 4. Mol Genet Metab 1998; 64: 25-35.
8. Dirksen U, Nishinakamura R, Groneck P, et al: Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression. J Clin Invest 1997; 100: 2211-17.
9. Parto K, Kallajoki M, Aho H, Simell O: Pulmonary alveolar proteinosis and glomerulonephritis in lysinuric protein intolerance: case report and autopsy findings of four pediatric patients. Hum Pathol 1994; 25: 400-7.
10. Ramirez J, Kieffer RF, Ball WC: Bronchopulmonary lavage in man. Ann Intern Med 1965; 63: 819-28.
11. Larson RK, Gordinier R: Pulmonary alveolar proteinosis: report of six cases, review of the literature, and formulation of a new theory. Ann Intern Med 1965; 62: 292-312.
12. Martin RJ, Coalson JJ, Rogers FM, et al: Pulmonary alveolar proteinosis: the diagnosis by segmental lavage. Am Rev Respir Dis 1980; 121: 819-25.
13. Stanley E, Lieschke GJ, Grail D, et al: Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 1994; 91: 5592-6.
14. Kitamura T, Tanaka N, Watanabe J, et al: Udiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 1999; 190: 875-80.
15. Honda Y, Takahashi H, Shijubo N, Kuroki Y, Akino T: Surfactant protein-A concentration in bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis. Chest 1993; 103: 496-9.
16. Honda Y, Kuroki Y, Matsuura E, et al: Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995; 152: 1860-6.
17. Griese M: Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J 1999; 13: 1455-76.
18. Ikegami M, Korfhagen TR, Bruno MD, Whitsett JA, Jobe AH: Surfactant metabolism in surfactant protein A-deficient mice. Am J Physiol 1997; 272: L479-85.
19. Yoshida M, Ikegami M, Reed JA, Chroneos ZC, Whitsett JA: GM-CSF regulates protein and lipid catabolism by alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2001; 280: L379-86.
20. Bonfield TL, Raychaudhuri B, Malur A, et al: PU.1 regulation of human alveolar macrophage differentiation requires granulocyte-macrophage colony-stimulating factor. Am J Physiol Lung Cell Mol Physiol 2003; 285: L1132-6.
21. Huffman JA, Hull WM, Dranoff G, Mulligan RC, Whitsett JA: Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. J Clin Invest 1996; 97: 649-55.
22. Nishinakamura R, Wiler R, Dirksen U, et al: The pulmonary alveolar proteinosis in granulocyte macrophage colony-stimulating factor/interleukins 3/5 beta c receptor-deficient mice is reversed by bone marrow transplantation. J Exp Med 1996; 183: 2657-62.
23. Reed JA, Ikegami M, Cianciolo ER, et al: Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice. Am J Physiol 1999; 276: L556-63.
24. Bonfield TL, Farver CF, Barna BP, et al: Peroxisome proliferator- activated receptor-γ is deficient in alveolar macrophages from patients with alveolar proteinosis. Am J Respir Cell Mol Biol 2003; 29: 677-82.
25. Hoffmann RM, Dauber JM, Rogers RM: Improvement in alveolar macrophage migration after therapeutic whole lung lavage in pulmonary alveolar proteinosis. Am Rev Respir Dis 1989; 139: 1030-2.
26. Golde DW, Territo M, Finley TN, Cline MJ: Defective lung macrophages in pulmonary alveolar proteinosis. Ann Intern Med 1976; 85: 304-9.
27. Nugent KM, Pesanti EL: Macrophage function in pulmonary alveolar proteinosis. Am Rev Respir Dis 1983; 127: 780-1.
28. Gonzalez-Rothi RJ, Harris JO: Pulmonary alveolar proteinosis. Further evaluation of abnormal alveolar macrophages. Chest 1986; 90: 656-61.
29. Kitamura T, Uchida K, Tanaka N, et al: Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000; 162: 658-62.
30. Thomassen MJ, Yi T, Raychaudhuri B, et al: Pulmonary alveolar proteinosis is a disease of decreased availability of GM-CSF rather than an intrinsic cellular defect. Clin Immunol 2000; 95: 85-92.
31. Bonfield TL, Russell D, Burgess S, Malur A, Kavuru MS, Thomassen MJ: Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am J Respir Cell Mol Biol 2002; 27: 481-6.
32. Seymour JF, Doyle IR, Nakata K, et al: Relationship of anti-GM-CSF antibody concentration surfactant, protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis. Thorax 2003; 58: 2552-7.
33. Latzin P, Tredan M, Wüst Y, et al: Anti-GM-CSF antibodies in paediatric pulmonary alveolar proteinosis. Thorax 2005; 60: 39-44.
34. Uchida K, Nakata K, Trapnell BC, et al: Granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood 2004; 103: 1089-98.
35. Prakash UB, Barham SS, Carpenter HA, Dines DE, Marsh MH: Pulmonary alveolar phospholipoproteinosis: experience with 34 cases and a review. Mayo Clin Proc 1987; 62: 499-518.
36. Goldstein LS, Kavuru MS, McCarthy PC, Christie HA, Farver C, Stoller JK: Pulmonary alveolar proteinosis. Clinical features and outcomes. Chest 1998; 114: 1357-62.
37. Lee KN, Levin DL, Webb WR, Chen D, Storto ML, Golden JA: Pulmonary alveolar proteinosis: high-resolution CT, chest radiographic, and functional correlations. Chest 1997; 111: 989-95.
38. Franquet T, Gimenez A, Bordes R, Rodriguez-Arias JM, Castella J: The crazy-paving pattern in exogenous lipoid pneumonia: CT-pathologic correlation. Am J Roentgenol 1998; 170: 315-17.
39. Holbert JM, Castello P, Wei L, Hoffman RM, Rogers RM: CT features of pulmonary alveolar proteinosis. Am J Roentgenol 2001; 176: 1287-94.
40. Johkoh T, Itoh H, Muller NL, et al: Crazy-paving appearance at thin-section CT: spectrum of disease and pathologic findings. Radiology 1999; 211: 155-60.
41. Martin RJ, Rogers RM, Myers MN: Pulmonary alveolar proteinosis: shunt fraction and lactic acid dehydrogenase concentration as aids to diagnosis. Am Rev Respir Dis 1978; 117: 1059-62.
42. Nakajima M, Manabe T, Niki Y, Matsushima T: Serum KL-6 level as a monitoring marker in a patient with pulmonary alveolar proteinosis. Thorax 1998; 53: 809-11.
43. Milleron BJ, Costabel U, Teschler H, et al: Bronchoalveolar lavage cell data in alveolar proteinosis. Am Rev Respir Dis 1991; 144: 1330-2.
44. Danel C, Israel-Biet D, Costabel U, Klech H: Therapeutic applications of bronchoalveolar lavage. Eur Respir J 1992; 5: 1173-5.
45. Burkhalter A, Silverman JF, Hopkins MB, Geisinger KR. Bronchoalveolar lavage cytology in pulmonary alveolar proteinosis. Am J Clin Pathol 1996; 106: 504-10.
46. Maygarden SJ, Iacocca MV, Funkhouser WK, Novotny DB: Pulmonary alveolar proteinosis: a spectrum of cytologic, histochemical, and ultrastructural findings in bronchoalveolar lavage fluid. Diagn Cytopathol 2001; 24: 389-95.
47. Selecky PA, Wasserman K, Benfield JR, Lippmann M. The clinical and physiological effect of whole-lung lavage in pulmonary alveolar proteinosis: a ten-year experience. Ann Thorac Surg 1977; 24: 451-60.
48. Freedman AP, Pelias A, Johnston RF, et al: Alveolar proteinosis lung lavage using partial cardiopulmonary bypass. Thorax 1981; 36: 543-5.
49. duBois RM, Branthwaire MA: Alveolar proteinosis: diagnosis and treatment over a 10 year period. Thorax 1983; 38: 360-3.
50. Kariman K, Kylstra JA, Spock A: Pulmonary alveolar proteinosis: prospective clinical experience in 23 patients for 15 years. Lung 1984; 162: 223-31.
51. Alberti A, Luisetti M, Braschi A, et al: Bronchoalveolar lavage fluid composition in alveolar proteinosis. Early changes after therapeutic lavage. Am J Respir Crit Care Med 1996; 154: 817-20.
52. Perez A, Rogers RM. Enhanced alveolar clearance with chest percussion therapy and positional changes during whole-lung lavage for alveolar proteinosis. Chest 2004; 125: 2351-6.
53. Beccaria M, Luisetti M, Rodi G, et al: Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J 2004; 23: 526-31.
54. Seymour JF, Presneill JJ, Schoch OD, et al: Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med 2001; 163: 524-31.
55. Kavuru MS, Sullivan EJ, Piccin R, Thomassen MJ, Stoller JK: Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000; 161: 1143-8.
56. Bonfield TL, Kavuru MS, Thomassen MJ: Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis. Clin Immunol 2002; 105: 342-50.
57. Kavuru M, Bonfield TL, Thomassen MJ: Plasmapheresis, GM-CSF, and alveolar proteinosis. Am J Roentgenol 2003; 167: 1036-7.
58. Parker LA, Nacotny DB: Recurrent alveolar proteinosis following double lung transplantation. Chest 1997; 111: 1457-8.